Drug Profile
Research programme: multiple sclerosis therapy - Quigley Pharma
Alternative Names: QR-442Latest Information Update: 20 Feb 2008
Price :
$50
*
At a glance
- Originator Quigley Pharma
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Multiple sclerosis
Most Recent Events
- 27 Oct 2005 Preclinical trials in Multiple sclerosis in USA (unspecified route)